 CHARLOTTESVILLE, VA ACCESSWIRE February 19, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approval to commence its Phase 3 study to investigate AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder AUD in Bulgaria in persons with certain target genotypes related to the serotonin transporter and receptor genes. This includes receiving approvals from both the Bulgarian Drug Agency and the Bulgarian Ethics Committee for Clinical Trials overseeing the study. Bulgaria is expected be an important country in our Phase 3 trial of AD04 in biomarker-positive study participants, stated William Stilley, Chief Executive Officer of Adial Pharmaceuticals. 